In gynecological cancers, particularly ovarian HGSC, epidrugs such as azacitidine and HDAC inhibitors play a pivotal role in ICI therapy by counteracting the immunosuppressive TME [193]. This evidence concerns the gene HDAC9 and female reproductive organ cancer.